Cumberland Pharmaceuticals Ownership
| CPIX Stock | USD 4.42 0.02 0.45% |
Shares in Circulation | First Issued 2006-03-31 | Previous Quarter 14.1 M | Current Value 14 M | Avarage Shares Outstanding 17 M | Quarterly Volatility 2.7 M |
Cumberland |
Cumberland Stock Ownership Analysis
About 44.0% of the company shares are held by company insiders. The book value of Cumberland Pharmaceuticals was currently reported as 1.64. The company recorded a loss per share of 0.46. Cumberland Pharmaceuticals last dividend was issued on the 29th of October 2010. The entity had 2:1 split on the 6th of July 2007. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceu operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more info on Cumberland Pharmaceuticals please contact the company at 615 255 0068 or go to https://www.cumberlandpharma.com.Besides selling stocks to institutional investors, Cumberland Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cumberland Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cumberland Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cumberland Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Cumberland Pharmaceuticals Insider Trades History
About 44.0% of Cumberland Pharmaceuticals are currently held by insiders. Unlike Cumberland Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cumberland Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cumberland Pharmaceuticals' insider trades
Cumberland Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cumberland Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cumberland Pharmaceuticals backward and forwards among themselves. Cumberland Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cumberland Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 8.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.7 K | Tower Research Capital Llc | 2024-12-31 | 2.2 K | Capital Advisors, Ltd. Llc | 2024-12-31 | 437 | Wells Fargo & Co | 2024-12-31 | 250 | Bank Of America Corp | 2024-12-31 | 65.0 | Jpmorgan Chase & Co | 2024-12-31 | 19.0 | Huntington National Bank | 2024-12-31 | 1.0 | Schonfeld Strategic Advisors Llc | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 507.2 K | Vanguard Group Inc | 2024-12-31 | 374.3 K |
Cumberland Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cumberland Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cumberland Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cumberland Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cumberland Pharmaceuticals Outstanding Bonds
Cumberland Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cumberland Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cumberland bonds can be classified according to their maturity, which is the date when Cumberland Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Cumberland Pharmaceuticals Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of March 2025 Other Reports | ViewVerify | |
10K | 7th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.